An insight into the interaction between clopidogrel and proton pump inhibitors

Current Drug Metabolism

Volumn 13, Issue 2, 2012, Pages 225-235

  Shah, Bhavik S ^a   Parmar, Sanjay A ^b   Mahajan, Shailaja ^c   Mehta, Anita A ^b  

^a Institute of Health Management Research   (India)

^b L M COLLEGE OF PHARMACY   (India)

^c H H University   (Germany)

Author keywords

Acute coronary syndrome (ACS); Clopidogrel; Cytochrome P450 (CYP); Drug drug interaction; Genetic polymorphism; Proton pump inhibitors (PPIs)

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; CLOPIDOGREL; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; ESOMEPRAZOLE; ITRACONAZOLE; LANSOPRAZOLE; NIFEDIPINE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ALLELE; ARTICLE; BIOLOGICAL ACTIVITY; CLINICAL PRACTICE; COMORBIDITY; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; ENZYME INHIBITION; ETHNICITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LOADING DRUG DOSE; MAINTENANCE THERAPY; RISK FACTOR; SINGLE DRUG DOSE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; PROTON PUMP INHIBITORS; TICLOPIDINE;

EID: 84857606031     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012798918390     Document Type: Article

References (79)

1. Meadows, T. A.; Bhatt, D. L., Clinical aspects of platelet inhibitors and thrombus formation. Circ. Res., 2007, 100(9), 1261-1275. (Pubitemid 46742917)
2. Yusuf, S.; Zhao, F.; Mehta, S. R.; Chrolavicius, S.; Tognoni, G.; Fox, K. K., Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med., 2001, 345(7), 494-502. (Pubitemid 32758501)
3. Steinhubl, S. R.; Berger, P. B.; Mann, J. T., 3rd; Fry, E. T.; DeLago, A.; Wilmer, C.; Topol, E. J., Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA, 2002, 288(19), 2411-2420. (Pubitemid 35340537)
4. Muller, I.; Besta, F.; Schulz, C.; Massberg, S.; Schonig, A.; Gawaz, M., Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb. Haemost., 2003, 89(5), 783-787. (Pubitemid 36603418)
5. Gurbel, P. A.; Bliden, K. P.; Hiatt, B. L.; O'Connor, C. M., Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation, 2003, 107(23), 2908-2913. (Pubitemid 36736631)
6. Lau, W. C.; Gurbel, P. A.; Watkins, P. B.; Neer, C. J.; Hopp, A. S.; Carville, D. G.; Guyer, K. E.; Tait, A. R.; Bates, E. R., Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation, 2004, 109(2), 166-171. (Pubitemid 38114134)
7. Wiviott, S. D.; Antman, E. M., Clopidogrel resistance: A new chapter in a fast-moving story. Circulation, 2004, 109(25), 3064-3067.
8. Gurbel, P. A.; Bliden, K. P., Platelet activation after stenting with heparin-coated versus noncoated stents. Am. Heart J., 2003, 146(4), E10.
9. Gurbel, P. A.; Tantry, U. S., Clopidogrel resistance? Thromb. Res., 2007, 120(3), 311-321. (Pubitemid 46881255)
10. Malinin, A.; Pokov, A.; Spergling, M.; Defranco, A.; Schwartz, K.; Schwartz, D.; Mahmud, E.; Atar, D.; Serebruany, V., Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: The VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb. Res., 2007, 119(3), 277-284. (Pubitemid 44918092)
11. Ang, L.; Palakodeti, V.; Khalid, A.; Tsimikas, S.; Idrees, Z.; Tran, P.; Clopton, P.; Zafar, N.; Bromberg-Marin, G.; Keramati, S.; Mahmud, E., Elevated Plasma Fibrinogen and Diabetes Mellitus Are Associated With Lower Inhibition of Platelet Reactivity With Clopidogrel. J. Am. Coll. Cardiol., 2008, 52(13), 1052-1059.
12. Angiolillo, D. J.; Fernandez-Ortiz, A.; Bernardo, E.; Alfonso, F.; Macaya, C.; Bass, T. A.; Costa, M. A., Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J. Am. Coll. Cardiol., 2007, 49(14), 1505-1516. (Pubitemid 46517957)
13. Nguyen, T. A.; Diodati, J. G.; Pharand, C., Resistance to clopidogrel: A review of the evidence. J. Am. Coll. Cardiol., 2005, 45(8), 1157-1164. (Pubitemid 40523131)
14. US Food and Drug Administration. Early Communication about an Ongoing Safety Review of Clopidogrel Bisulfate (marketed as Plavix) -May 2009. http://www.fda.gov/Drugs/DrugSafety/ucm079520.htm (accessed July 19, 2011).
15. US Food and Drug Administration . Plavix (clopidogrel bisulfate) 75 mg tablets. Detailed View: Safety Labeling Changes Approved by FDA Center for Drug Evaluation and Research (CDER) -May 2009. http://www.fda.gov/Safety/MedWatch/ SafetyInformation/ucm1651 66.htm (accessed July 19, 2011).
16. European Medicines Agency. Public Statement on Possible Interaction Between Clopidogrel and Proton Pump Inhibitors. May 2009. http://www.emea. europa.eu/humandocs/PDFs/EPAR/Plavix/32895 609en.pdf (accessed July 19, 2011).
17. Savi, P.; Combalbert, J.; Gaich, C.; Rouchon, M. C.; Maffrand, J. P.; Berger, Y.; Herbert, J. M., The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb. Haemost., 1994, 72(2), 313-317. (Pubitemid 24251300)
18. Product package insert for clopidogrel (PLAVIX ®) available online. http://products.sanofi-Aventis.us/PLAVIX/PLAVIX.html (accessed January 03, 2011).
19. Savi, P.; Pereillo, J. M.; Uzabiaga, M. F.; Combalbert, J.; Picard, C.; Maffrand, J. P.; Pascal, M.; Herbert, J. M., Identification and biological activity of the active metabolite of clopidogrel. Thromb. Haemost., 2000, 84(5), 891-896.
20. Pereillo, J. M.; Maftouh, M.; Andrieu, A.; Uzabiaga, M. F.; Fedeli, O.; Savi, P.; Pascal, M.; Herbert, J. M.; Maffrand, J. P.; Picard, C., Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab. Dispos., 2002, 30(11), 1288-1295. (Pubitemid 35265838)
21. Small, D. S.; Farid, N. A.; Payne, C. D.; Weerakkody, G. J.; Li, Y. G.; Brandt, J. T.; Salazar, D. E.; Winters, K. J., Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel. The Journal of Clinical Pharmacology, 2008, 48(4), 475-484. (Pubitemid 351389118)
22. Lotfi, A.; Schweiger, M. J.; Giugliano, G. R.; Murphy, S. A.; Cannon, C. P., High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients-A Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis. Am. Heart. J., 2008, 155(5), 954-958.
23. Kazui, M.; Nishiya, Y.; Ishizuka, T.; Hagihara, K.; Farid, N. A.; Okazaki, O.; Ikeda, T.; Kurihara, A., Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos., 2010, 38(1), 92-99.
24. Suh, J. W.; Koo, B. K.; Zhang, S. Y.; Park, K. W.; Cho, J. Y.; Jang, I. J.; Lee, D. S.; Sohn, D. W.; Lee, M. M.; Kim, H. S., Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ, 2006, 174(12), 1715-1722.
25. Farid, N. A.; Payne, C. D.; Small, D. S.; Winters, K. J.; Ernest, C. S., 2nd; Brandt, J. T.; Darstein, C.; Jakubowski, J. A.; Salazar, D. E., Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin. Pharmacol. Ther., 2007, 81(5), 735-741. (Pubitemid 46625113)
26. Siller-Matula, J. M.; Lang, I.; Christ, G.; Jilma, B., Calciumchannel blockers reduce the antiplatelet effect of clopidogrel. J. Am. Coll. Cardiol., 2008, 52(19), 1557-1563.
27. Sibbing, D.; von Beckerath, N.; Morath, T.; Stegherr, J.; Mehilli, J.; Sarafoff, N.; Braun, S.; Schulz, S.; Schomig, A.; Kastrati, A., Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur. Heart. J., 2010, 31(10), 1205-1211.
28. Lau, W. C.; Waskell, L. A.; Watkins, P. B.; Neer, C. J.; Horowitz, K.; Hopp, A. S.; Tait, A. R.; Carville, D. G.; Guyer, K. E.; Bates, E. R., Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction. Circulation, 2003, 107(1), 32-37. (Pubitemid 36070929)
29. Saw, J.; Steinhubl, S. R.; Berger, P. B.; Kereiakes, D. J.; Serebruany, V. L.; Brennan, D.; Topol, E. J., Lack of adverse clopidogrel-Atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation, 2003, 108(8), 921-924. (Pubitemid 37048218)
30. Serebruany, V. L.; Midei, M. G.; Malinin, A. I.; Oshrine, B. R.; Lowry, D. R.; Sane, D. C.; Tanguay, J. F.; Steinhubl, S. R.; Berger, P. B.; O'Connor, C. M.; Hennekens, C. H., Absence of interaction between atorvastatin or other statins and clopidogrel: Results from the interaction study. Arch. Intern. Med., 2004, 164(18), 2051-2057. (Pubitemid 39390564)
31. Siasos, G.; Tousoulis, D.; Stefanadis, C., Multiple Mechanisms Affect the Clopidogrel Response. J. Am. Coll. Cardiol., 2009, 53(10), 900-A-901.
32. Ancrenaz, V.; Daali, Y.; Fontana, P.; Besson, M.; Samer, C.; Dayer, P.; Desmeules, J., Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. Curr. Drug Metab., 2010, 11(8), 667-677.
33. Judge, H. M.; Patil, S. B.; Buckland, R. J.; Jakubowski, J. A.; Storey, R. F., Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel. J. Thromb. Haemost., 2010, 8(8), 1820-1827.
34. Bhatt, D. L.; Scheiman, J.; Abraham, N. S.; Antman, E. M.; Chan, F. K.; Furberg, C. D.; Johnson, D. A.; Mahaffey, K. W.; Quigley, E. M.; Harrington, R. A.; Bates, E. R.; Bridges, C. R.; Eisenberg, M. J.; Ferrari, V. A.; Hlatky, M. A.; Kaul, S.; Lindner, J. R.; Moliterno, D. J.; Mukherjee, D.; Schofield, R. S.; Rosenson, R. S.; Stein, J. H.; Weitz, H. H.; Wesley, D. J., ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J. Am. Coll. Cardiol., 2008, 52(18), 1502-1517.
35. Gilard, M.; Arnaud, B.; Le Gal, G.; Abgrall, J. F.; Boschat, J., Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J. Thromb. Haemost., 2006, 4(11), 2508-2509. (Pubitemid 44575451)
36. Gilard, M.; Arnaud, B.; Cornily, J. C.; Le Gal, G.; Lacut, K.; Le Calvez, G.; Mansourati, J.; Mottier, D.; Abgrall, J. F.; Boschat, J., Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J. Am. Coll. Cardiol., 2008, 51(3), 256-260.
37. Li, X. Q.; Andersson, T. B.; Ahlstrom, M.; Weidolf, L., Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab. Dispos., 2004, 32(8), 821-827. (Pubitemid 38955611)
38. Pearce, R. E.; Rodrigues, A. D.; Goldstein, J. A.; Parkinson, A., Identification of the human P450 enzymes involved in lansoprazole metabolism. J. Pharmacol. Exp. Ther., 1996, 277(2), 805-816. (Pubitemid 27168992)
39. Siller-Matula, J. M.; Spiel, A. O.; Lang, I. M.; Kreiner, G.; Christ, G.; Jilma, B., Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am. Heart. J., 2009, 157(1), 148 e141-145.
40. Sibbing, D.; Morath, T.; Stegherr, J.; Braun, S.; Vogt, W.; Hadamitzky, M.; Schomig, A.; Kastrati, A.; von Beckerath, N., Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb. Haemost., 2009, 101(4), 714-719.
41. O'Donoghue, M. L.; Braunwald, E.; Antman, E. M.; Murphy, S. A.; Bates, E. R.; Rozenman, Y.; Michelson, A. D.; Hautvast, R. W.; Ver Lee, P. N.; Close, S. L.; Shen, L.; Mega, J. L.; Sabatine, M. S.; Wiviott, S. D., Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials. Lancet, 2009, 374(9694), 989-997.
42. Pezalla, E.; Day, D.; Pulliadath, I., Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J. Am. Coll. Cardiol., 2008, 52(12), 1038-1039; author reply 1039.
43. Juurlink, D. N.; Gomes, T.; Ko, D. T.; Szmitko, P. E.; Austin, P. C.; Tu, J. V.; Henry, D. A.; Kopp, A.; Mamdani, M. M., A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ, 2009, 180(7), 713-718.
44. Mega, J. L.; Close, S. L.; Wiviott, S. D.; Shen, L.; Hockett, R. D.; Brandt, J. T.; Walker, J. R.; Antman, E. M.; Macias, W.; Braunwald, E.; Sabatine, M. S., Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med., 2009, 360(4), 354-362.
45. Ho, P. M.; Peterson, E. D.; Wang, L.; Magid, D. J.; Fihn, S. D.; Larsen, G. C.; Jesse, R. A.; Rumsfeld, J. S., Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA, 2008, 299(5), 532-539. (Pubitemid 351222546)
46. Stockl, K. M.; Le, L.; Zakharyan, A.; Harada, A. S.; Solow, B. K.; Addiego, J. E.; Ramsey, S., Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch. Intern. Med., 2010, 170(8), 704-710.
47. Stanek, E. J.; Aubert, R. E.; Rolf, P.; Kreutz, R. P.; Yao, J.; Breall, J. A., A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: The Clopidogrel Medco Outcomes study. In 32nd Annual SCAI Scientific Sessions, Las Vegas, Nevada, 2009 (Abstract).
48. Kreutz, R. P.; Stanek, E. J.; Aubert, R.; Yao, J.; Breall, J. A.; Desta, Z.; Skaar, T. C.; Teagarden, J. R.; Frueh, F. W.; Epstein, R. S.; Flockhart, D. A., Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: The clopidogrel Medco outcomes study. Pharmacotherapy, 2010, 30(8), 787-796.
49. Rassen, J. A.; Choudhry, N. K.; Avorn, J.; Schneeweiss, S., Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation, 2009, 120(23), 2322-2329.
50. Bhatt, D. L.; Cryer, B.; Contant, C. F., COGENT: A prospective, randomized, placebo-controlled trial of omeprazole in patients receiving aspirin and clopidogrel. . In Transvascular Cardiovascular Therapeutics Annual Meeting, San Francisco, USA, 2009 (Abstract).
51. Bhatt, D. L.; Cryer, B. L.; Contant, C. F.; Cohen, M.; Lanas, A.; Schnitzer, T. J.; Shook, T. L.; Lapuerta, P.; Goldsmith, M. A.; Laine, L.; Scirica, B. M.; Murphy, S. A.; Cannon, C. P., Clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med., 2010, 363(20), 1909-1917.
52. Ray, W. A.; Murray, K. T.; Griffin, M. R.; Chung, C. P.; Smalley, W. E.; Hall, K.; Daugherty, J. R.; Kaltenbach, L. A.; Stein, C. M., Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: A cohort study. Ann. Intern. Med., 2010, 152(6), 337-345.
53. Dunn, S. P.; Macaulay, T. E.; Brennan, D. M.; Campbell, C. L.; Charnigo, R. J.; Smyth, S. S.; Berger, B. B.; Steinhubl, S. R.; Topol, E. J., Baseline proton pump inhibitors use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation, 2008, 118, S-815 (Abstract).
54. Simon, T.; Verstuyft, C.; Mary-Krause, M.; Quteineh, L.; Drouet, E.; Meneveau, N.; Steg, P. G.; Ferrieres, J.; Danchin, N.; Becquemont, L., Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med., 2009, 360(4), 363-375.
55. Lapuerta, P. Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1). ClinicalTrials.gov Identifier: NCT00557921, Available online. http://clinicaltrials.gov/ct2/show/NCT00557921 (accessed July 18, 2011).
56. Ingelman-Sundberg, M.; Sim, S. C., Intronic polymorphisms of cytochromes P450. Hum. Genomics, 2010, 4(6), 402-405.
57. Farid, N. A.; Kurihara, A.; Wrighton, S. A., Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin. Pharmacol., 2010, 50 (2), 126-142.
58. Brandt, J. T.; Close, S. L.; Iturria, S. J.; Payne, C. D.; Farid, N. A.; Ernest, C. S., 2nd; Lachno, D. R.; Salazar, D.; Winters, K. J., Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost., 2007, 5(12), 2429-2436. (Pubitemid 350154353)
59. Kim, K. A.; Park, P. W.; Hong, S. J.; Park, J. Y., The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: A possible mechanism for clopidogrel resistance. Clin. Pharmacol. Ther., 2008, 84(2), 236-242.
60. CYP2C19 allele nomenclature, available online. http://www.cypalleles.ki. se/cyp2c19.htm (accessed July 18, 2011).
61. O'Donnell, C. J.; Larson, M. G.; Feng, D.; Sutherland, P. A.; Lindpaintner, K.; Myers, R. H.; D'Agostino, R. A.; Levy, D.; Tofler, G. H., Genetic and environmental contributions to platelet aggregation: The Framingham heart study. Circulation, 2001, 103(25), 3051-3056. (Pubitemid 32587850)
62. Wiviott, S. D.; Braunwald, E.; McCabe, C. H.; Montalescot, G.; Ruzyllo, W.; Gottlieb, S.; Neumann, F. J.; Ardissino, D.; De Servi, S.; Murphy, S. A.; Riesmeyer, J.; Weerakkody, G.; Gibson, C. M.; Antman, E. M., Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med., 2007, 357(20), 2001-2015. (Pubitemid 350106708)
63. Wallentin, L.; Varenhorst, C.; James, S.; Erlinge, D.; Braun, O. O.; Jakubowski, J. A.; Sugidachi, A.; Winters, K. J.; Siegbahn, A., Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur. Heart. J., 2008, 29(1), 21-30.
64. Trenk, D.; Hochholzer, W.; Fromm, M. F.; Chialda, L. E.; Pahl, A.; Valina, C. M.; Stratz, C.; Schmiebusch, P.; Bestehorn, H. P.; Buttner, H. J.; Neumann, F. J., Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J. Am. Coll. Cardiol., 2008, 51(20), 1925-1934. (Pubitemid 351636443)
65. Anderson, J. L.; Adams, C. D.; Antman, E. M.; Bridges, C. R.; Califf, R. M.; Casey, D. E., Jr.; Chavey, W. E., 2nd; Fesmire, F. M.; Hochman, J. S.; Levin, T. N.; Lincoff, A. M.; Peterson, E. D.; Theroux, P.; Wenger, N. K.; Wright, R. S.; Smith, S. C., Jr.; Jacobs, A. K.; Halperin, J. L.; Hunt, S. A.; Krumholz, H. M.; Kushner, F. G.; Lytle, B. W.; Nishimura, R.; Ornato, J. P.; Page, R. L.; Riegel, B., ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non STElevation Myocardial Infarction): Developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation, 2007, 116(7), e148-304.
66. Sim, S. C.; Risinger, C.; Dahl, M. L.; Aklillu, E.; Christensen, M.; Bertilsson, L.; Ingelman-Sundberg, M., A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther., 2006, 79(1), 103-113. (Pubitemid 43069582)
67. Stehle, S.; Kirchheiner, J.; Lazar, A.; Fuhr, U., Pharmacogenetics of oral anticoagulants: A basis for dose individualization. Clin. Pharmacokinet., 2008, 47(9), 565-594.
68. Baldwin, R. M.; Ohlsson, S.; Pedersen, R. S.; Mwinyi, J.; Ingelman-Sundberg, M.; Eliasson, E.; Bertilsson, L., Increased omeprazole metabolism in carriers of the CYP2C19 17 allele; a pharmacokinetic study in healthy volunteers. Br. J. Clin. Pharmacol., 2008, 65(5), 767-774. (Pubitemid 351535091)
69. Li-Wan-Po, A.; Girard, T.; Farndon, P.; Cooley, C.; Lithgow, J., Pharmacogenetics of CYP2C19: Functional and clinical implications of a new variant CYP2C19 17. Br. J. Clin. Pharmacol., 2010, 69(3), 222-230.
70. Geisler, T.; Schaeffeler, E.; Dippon, J.; Winter, S.; Buse, V.; Bischofs, C.; Zuern, C.; Moerike, K.; Gawaz, M.; Schwab, M., CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics, 2008, 9(9), 1251-1259.
71. Xie, H.-G.; Zou, J.-J.; Hu, Z.-Y.; Zhang, J.-J.; Ye, F.; Chen, S.-L., Individual variability in the disposition of and response to clopidogrel: Pharmacogenomics and beyond. Pharmacology & Therapeutics, 2011, 129(3), 267-289.
72. Sibbing, D.; Koch, W.; Gebhard, D.; Schuster, T.; Braun, S.; Stegherr, J.; Morath, T.; Schomig, A.; von Beckerath, N.; Kastrati, A., Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation, 2010, 121(4), 512-518.
73. Lordkipanidze, M.; Pharand, C.; Schampaert, E.; Turgeon, J.; Palisaitis, D. A.; Diodati, J. G., A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur. Heart J., 2007, 28(14), 1702-1708. (Pubitemid 47227104)
74. Ferguson, A. D.; Dokainish, H.; Lakkis, N., Aspirin and clopidogrel response variability: Review of the published literature. Tex. Heart Inst. J., 2008, 35(3), 313-320.
75. Gasparyan, A. Y., Aspirin and clopidogrel resistance: Methodological challenges and opportunities. Vasc. Health Risk Manag., 2010, 6, 109-112.
76. Abraham, N. S.; Hlatky, M. A.; Antman, E. M.; Bhatt, D. L.; Bjorkman, D. J.; Clark, C. B.; Furberg, C. D.; Johnson, D. A.; Kahi, C. J.; Laine, L.; Mahaffey, K. W.; Quigley, E. M.; Scheiman, J.; Sperling, L. S.; Tomaselli, G. F., ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J. Am. Coll. Cardiol., 2010, 56(24), 2051-2066.
77. Tantry, U. S.; Kereiakes, D. J.; Gurbel, P. A., Clopidogrel and proton pump inhibitors: Influence of pharmacological interactions on clinical outcomes and mechanistic explanations. JACC Cardiovasc. Interv., 2011, 4(4), 365-380.
78. US Food and Drug Administration. Information on Clopidogrel Bisulfate (marketed as Plavix). http://www.fda.gov/Drugs/Drug-Safety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm190836.htm (accessed July 2011).
79. European Medicines Agency. Public Statement on Interaction between clopidogrel and proton-pump inhibitors. Available online at. http://www.ema.europa.eu/docs/en-GB/document-library/Public-statement/2010/03/ WC500076346.pdf (accessed July 24, 2011).